<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511186</url>
  </required_header>
  <id_info>
    <org_study_id>AP REN 01-01</org_study_id>
    <nct_id>NCT00511186</nct_id>
  </id_info>
  <brief_title>A Study in Sepsis Patients With Renal Failure</brief_title>
  <official_title>A Phase-IIa, Double-blind, Randomized, Placebo-controlled Study on the Safety and Early Efficacy of Alkaline Phosphatase in Sepsis Patients With Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AM-Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AM-Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of AP in sepsis&#xD;
      patients with renal failure and to investigate the effect of AP on inflammatory and clinical&#xD;
      parameters in sepsis patients with renal failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE FOR THE STUDY&#xD;
&#xD;
      A previous clinical study conducted in centers in The Netherlands and Belgium have shown a&#xD;
      substantial clinical benefit of AP treatment in patients with sepsis and associated acute&#xD;
      renal failure (see Introduction above). The latter results require confirmation in a&#xD;
      prospective study, as the current subject of this Protocol.&#xD;
&#xD;
      Choice of Drugs&#xD;
&#xD;
      The proposed study medication (AP) is identical to the study medication used in the previous&#xD;
      clinical study in sepsis patients with single or multiple end-organ failure. Since there is&#xD;
      no current proven treatment for these patients, the controls (as in previous studies) is&#xD;
      placebo.&#xD;
&#xD;
      Choice of patient population&#xD;
&#xD;
      The aim is to enroll a maximum of 26 patients positive for sepsis with an APACHE score of ≥20&#xD;
      and ≤28 (determined within 24 hours of entry), and who will be analyzed on an intention to&#xD;
      treat (ITT) basis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sufficient POC to switch development from bovine AP to recombinant AP&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haematology, biochemistry, and microbiological evaluation. Adverse event monitoring.</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of AP on inflammatory parameters in sepsis patients with renal failure.</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of AP on clinical variables in sepsis patients with renal failure.</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of AP on renal function markers in sepsis patients with renal failure.</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Sepsis</condition>
  <condition>Bacterial Infections and Mycoses</condition>
  <arm_group>
    <arm_group_label>Bovine Intestinal AP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10&quot; bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Intravenous administration of 10&quot; bolus and 48h continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIAP</intervention_name>
    <description>AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H</description>
    <arm_group_label>Bovine Intestinal AP</arm_group_label>
    <other_name>AP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between the age of 18 and 80 years.&#xD;
&#xD;
          -  Proven or suspected infection.&#xD;
&#xD;
          -  Two out of four SIRS criteria of systemic inflammation, existing for less than 24&#xD;
             hours after admission in the intensive care unit, as follows:&#xD;
&#xD;
               -  Core temperature higher then 38 degree Celsius or lower then 36 degree Celsius.&#xD;
&#xD;
               -  Heart rate above 90 beats/min (unless the patient has a medical condition known&#xD;
                  to increase heart rate or is receiving treatment that would prevent tachycardia).&#xD;
&#xD;
               -  Respiratory rate above 20 breaths/min, a PaCO2 lower then 32mmHg or the use of&#xD;
                  mechanical ventilation for an acute respiratory process.&#xD;
&#xD;
               -  White-cell count above 12,000/mm3 or below 4,000/mm3 or a differential count&#xD;
                  showing &gt;10 percent immature neutrophils.&#xD;
&#xD;
          -  Acute renal failure, defined as&#xD;
&#xD;
               -  Rise in serum creatinine level to ≥150μmol/L within the previous 48 hours, in the&#xD;
                  absence of primary underlying renal disease OR&#xD;
&#xD;
               -  Minimally a stage 1 Kidney Injury according to AKIN creatinine criteria: Increase&#xD;
                  in serum creatinine ≥26.2µmol/L (0.3mg/dL) or increase to ≥150% (≥1.5 -fold) from&#xD;
                  baseline in the previous 48 hours in the absence of primary underlying renal&#xD;
                  disease and where baseline creatinine is less than 150 µmol/L) OR&#xD;
&#xD;
               -  Minimally a stage 1 Kidney Injury according to AKIN Urine Output criteria: Urine&#xD;
                  Output of ≤ 0.5mg/kg/h for ≥6h and following adequate fluid resuscitation when&#xD;
                  applicable, in the absence of underlying primary renal disease and where baseline&#xD;
                  creatinine is less than 150µmol/L)&#xD;
&#xD;
          -  Written informed consent obtained prior to any study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women or nursing mothers and fecund females who are not on effective&#xD;
             contraception (chemical: pill; or mechanical: IUD)&#xD;
&#xD;
          -  Patients already on dialysis (RTT) at entry&#xD;
&#xD;
          -  Known HIV (sero-positive) patients&#xD;
&#xD;
          -  Patients receiving immunosuppressant therapy or on chronic high doses of steroids&#xD;
             equivalent to prednisone 1mg/Kg/day&#xD;
&#xD;
          -  Patients expected to have rapidly fatal disease within 24 hours&#xD;
&#xD;
          -  Known confirmed gram-positive sepsis&#xD;
&#xD;
          -  Known confirmed fungal sepsis&#xD;
&#xD;
          -  Acute pancreatitis with no established source of infection&#xD;
&#xD;
          -  Patients not expected to survive for 28 days due to other medical conditions such as&#xD;
             end-stage neoplasm or other diseases&#xD;
&#xD;
          -  Participation in another investigational study within 90 days prior to start of the&#xD;
             study which might interfere with this study&#xD;
&#xD;
          -  Any previous administration of active study medication.&#xD;
&#xD;
          -  Known allergy for dairy (bovine) products including cow milk.&#xD;
&#xD;
          -  Sepsis without renal failure as defined in the Entry Criteria.&#xD;
&#xD;
          -  History of chronic renal failure or history of persistent creatinine level equal or&#xD;
             greater than 150umol/L prior to entry for reasons other than the current sepsis&#xD;
             condition&quot;.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor J G van der Hoeven, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center St Radboud, Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Antwerp (UZA)</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc-UCL</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Nijmegen University Medical Center St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Clinics</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis lokatie GZG</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.am-pharma.com</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Pickkers P, Heemskerk S, Schouten J, Laterre PF, Vincent JL, Beishuizen A, Jorens PG, Spapen H, Bulitta M, Peters WH, van der Hoeven JG. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012 Jan 23;16(1):R14. doi: 10.1186/cc11159.</citation>
    <PMID>22269279</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <last_update_submitted>March 30, 2012</last_update_submitted>
  <last_update_submitted_qc>March 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Alkaline Phosphatase</keyword>
  <keyword>inflammation</keyword>
  <keyword>infection</keyword>
  <keyword>renal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Bacterial Infections and Mycoses</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

